EI
GNMK

EAM Investors’s GenMark Diagnostics, Inc GNMK Stock Holding History

EAM Investors’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-267,560
Closed -$3.94M – 389
2020
Q2 		$3.94M Buy
+267,560
New +$2.72M 0.87% 10
2017
Q1 		– Sell
-79,355
Closed -$971K – 396
2016
Q4 		$971K Buy
+79,355
New +$942K 0.13% 263

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

EAM Investors's GNMK Position: Q3 2020 in Review

EAM Investors sold out of GenMark Diagnostics, Inc (GNMK) in Q3 2020, closing a stake of 267,560 shares — an estimated $3.94M sold.

EAM Investors first reported a position in GNMK in Q4 2016 and held it in 2 quarters. The position peaked at $3.94M in Q2 2020. 163 funds tracked by Wall St. Rank hold GNMK as of Q3 2020.

  • EAM Investors reported no remaining GenMark Diagnostics, Inc position as of Q3 2020 after selling out during the quarter.
  • EAM Investors sold 267,560 GenMark Diagnostics, Inc shares in Q3 2020, an estimated $3.94M.
  • EAM Investors first reported a position in GenMark Diagnostics, Inc in Q4 2016 and held it in 2 quarters.
  • EAM Investors's GenMark Diagnostics, Inc position peaked at $3.94M in Q2 2020.
  • 163 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q3 2020.

Based on EAM Investors's 13F filing for Q3 2020, filed 13 Nov 2020.